Journal Article
. 2008 Apr;358(16).
doi: 10.1056/NEJMoa0707056.

Weekly paclitaxel in the adjuvant treatment of breast cancer

Joseph A Sparano 1 Molin Wang  Silvana Martino  Vicky Jones  Edith A Perez  Tom Saphner  Antonio C Wolff  George W Sledge  William C Wood  Nancy E Davidson  
  • PMID: 18420499
  •     11 References
  •     237 citations


Background: We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer.

Methods: We enrolled 4950 women with axillary lymph node-positive or high-risk, lymph node-negative breast cancer. After randomization, all patients first received 4 cycles of intravenous doxorubicin and cyclophosphamide at 3-week intervals and were then assigned to intravenous paclitaxel or docetaxel given at 3-week intervals for 4 cycles or at 1-week intervals for 12 cycles. The primary end point was disease-free survival.

Results: As compared with patients receiving standard therapy (paclitaxel every 3 weeks), the odds ratio for disease-free survival was 1.27 among those receiving weekly paclitaxel (P=0.006), 1.23 among those receiving docetaxel every 3 weeks (P=0.02), and 1.09 among those receiving weekly docetaxel (P=0.29) (with an odds ratio >1 favoring the groups receiving experimental therapy). As compared with standard therapy, weekly paclitaxel was also associated with improved survival (odds ratio, 1.32; P=0.01). An exploratory analysis of a subgroup of patients whose tumors expressed no human epidermal growth factor receptor type 2 protein found similar improvements in disease-free and overall survival with weekly paclitaxel treatment, regardless of hormone-receptor expression. Grade 2, 3, or 4 neuropathy was more frequent with weekly paclitaxel than with paclitaxel every 3 weeks (27% vs. 20%).

Conclusions: Weekly paclitaxel after standard adjuvant chemotherapy with doxorubicin and cyclophosphamide improves disease-free and overall survival in women with breast cancer. ( number, NCT00004125 [].).

HER2 and response to paclitaxel in node-positive breast cancer.
Daniel F Hayes, Ann D Thor, +14 authors, Cancer and Leukemia Group B (CALGB) Investigators.
N Engl J Med, 2007 Oct 12; 357(15). PMID: 17928597
Highly Cited.
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I Craig Henderson, Donald A Berry, +16 authors, Larry Norton.
J Clin Oncol, 2003 Mar 15; 21(6). PMID: 12637460
Highly Cited.
Current indications for chemotherapy in prostate cancer patients.
Fabio Calabrò, Cora N Sternberg.
Eur Urol, 2006 Sep 30; 51(1). PMID: 17007996
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
S E Jones, J Erban, +12 authors, P M Ravdin.
J Clin Oncol, 2005 Aug 20; 23(24). PMID: 16110015
Highly Cited.
Adjuvant docetaxel for node-positive breast cancer.
Miguel Martin, Tadeusz Pienkowski, +30 authors, Breast Cancer International Research Group 001 Investigators.
N Engl J Med, 2005 Jun 03; 352(22). PMID: 15930421
Highly Cited.
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
J A Sparano.
Clin Breast Cancer, 2002 Mar 20; 1(1). PMID: 11899388
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Clifford A Hudis, William E Barlow, +8 authors, Jo Anne Zujewski.
J Clin Oncol, 2007 May 22; 25(15). PMID: 17513820
Highly Cited.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Eleftherios P Mamounas, John Bryant, +7 authors, Norman Wolmark.
J Clin Oncol, 2005 May 18; 23(16). PMID: 15897552
Highly Cited.
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Sibylle Loibl, Gunter von Minckwitz, +8 authors, Sherko Kümmel.
Breast Cancer Res, 2008 Sep 18; 10(5). PMID: 18796139    Free PMC article.
Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Katsumasa Kuroi, Kojiro Shimozuma, +7 authors, Frederick H Hausheer.
Support Care Cancer, 2008 Dec 18; 17(8). PMID: 19089463
Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center.
Lincy S Lal, Donna L Gerber, Jason Lau, William Dana.
Support Care Cancer, 2009 Feb 03; 17(10). PMID: 19184123
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
Jason A Zell, Walter Y Tsang, +2 authors, Hoda Anton-Culver.
Breast Cancer Res, 2009 Feb 21; 11(1). PMID: 19228416    Free PMC article.
Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.
Keun Seok Lee, Jungsil Ro, +6 authors, Kyung Hwan Shin.
Invest New Drugs, 2009 Feb 21; 28(1). PMID: 19229476
TLE3 as a candidate biomarker of response to taxane therapy.
Swati A Kulkarni, David G Hicks, +9 authors, Douglas T Ross.
Breast Cancer Res, 2009 Mar 25; 11(2). PMID: 19309506    Free PMC article.
Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.
Sara López-Tarruella, Miguel Martín.
Breast Cancer Res, 2009 Apr 07; 11(2). PMID: 19344489    Free PMC article.
Adjuvant chemotherapy for early breast cancer in the elderly.
Mary Leung, Iulianna Shapira, Thomas Bradley, Daniel R Budman.
Curr Treat Options Oncol, 2009 Apr 11; 10(3-4). PMID: 19360475
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
Robert Wesolowski, David Peereboom, +2 authors, George Thomas Budd.
Invest New Drugs, 2009 May 13; 28(4). PMID: 19434371
Optimal use of taxanes in metastatic breast cancer.
K M King, S Lupichuk, +4 authors, S Rix.
Curr Oncol, 2009 Jun 16; 16(3). PMID: 19526080    Free PMC article.
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
Fatima Cardoso, Philippe L Bedard, +8 authors, ESO-MBC Task Force.
J Natl Cancer Inst, 2009 Aug 07; 101(17). PMID: 19657108    Free PMC article.
Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer.
Shannon Puhalla, Adam Brufsky.
Biologics, 2009 Aug 27; 2(3). PMID: 19707381    Free PMC article.
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Margot Burnell, Mark N Levine, +11 authors, Lois E Shepherd.
J Clin Oncol, 2009 Nov 11; 28(1). PMID: 19901117    Free PMC article.
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
Philippe L Bedard, Angelo Di Leo, Martine J Piccart-Gebhart.
Nat Rev Clin Oncol, 2009 Dec 10; 7(1). PMID: 19997076
A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.
Stacy Moulder, Hailun Li, +6 authors, George W Sledge.
Breast Cancer Res Treat, 2009 Dec 17; 119(3). PMID: 20012354    Free PMC article.
Five-year survival of metastatic pancreatic carcinoma: a study of courage and hope.
Ben M Chue.
Gastrointest Cancer Res, 2010 Jan 20; 3(5). PMID: 20084164    Free PMC article.
Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.
Gisele A Sarosy, Mahrukh M Hussain, +7 authors, Elise C Kohn.
Cancer, 2010 Jan 22; 116(6). PMID: 20091841    Free PMC article.
Chemotherapy: dose-dense treatment for triple-negative breast cancer.
Eitan Amir, Alberto Ocana, +2 authors, Bostjan Seruga.
Nat Rev Clin Oncol, 2010 Feb 02; 7(2). PMID: 20118978
Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].
Serena Di Cosimo, José Baselga.
Nat Rev Clin Oncol, 2010 Feb 04; 7(3). PMID: 20125090
Triple-negative breast cancer: role of specific chemotherapy agents.
Steven J Isakoff.
Cancer J, 2010 Feb 19; 16(1). PMID: 20164691    Free PMC article.
Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.
Bernd Gerber, Mathias Freund, Toralf Reimer.
Dtsch Arztebl Int, 2010 Mar 06; 107(6). PMID: 20204119    Free PMC article.
Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
Carmen Frías, Javier Cortés, +2 authors, Miguel Ángel Casado.
Clin Transl Oncol, 2010 Oct 16; 12(10). PMID: 20947484
Recent studies that influence the chemotherapeutic paradigm in the management of advanced ovarian cancer.
Maurie Markman.
F1000 Med Rep, 2010 Oct 16; 2. PMID: 20948857    Free PMC article.
Triple-negative breast cancer: epidemiology and management options.
Shaheenah Dawood.
Drugs, 2010 Nov 18; 70(17). PMID: 21080741
Optimizing dose-dense regimens for early-stage breast cancer.
Patrick G Morris, Clifford A Hudis.
Nat Rev Clin Oncol, 2010 Dec 01; 7(12). PMID: 21116238
Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel.
Chun-Fang Zou, Luoqi Jia, +7 authors, Yinhua Yu.
BMC Cancer, 2011 Jan 20; 11. PMID: 21244707    Free PMC article.
Breast cancer and fertility preservation.
S Samuel Kim, Jennifer Klemp, Carol Fabian.
Fertil Steril, 2011 Jan 29; 95(5). PMID: 21272867    Free PMC article.
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Francesco Nuzzo, Alessandro Morabito, +16 authors, Andrea de Matteis.
BMC Cancer, 2011 Feb 18; 11. PMID: 21324184    Free PMC article.
Weekly paclitaxel in ovarian cancer-the latest success story.
A Jain, B Dubashi, K S Reddy, P Jain.
Curr Oncol, 2011 Feb 19; 18(1). PMID: 21331277    Free PMC article.
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
Heather L McArthur, Hope Rugo, +30 authors, Maura N Dickler.
Clin Cancer Res, 2011 Feb 26; 17(10). PMID: 21350003    Free PMC article.
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
Roisin M Connolly, Michelle A Rudek, +10 authors, Antonio C Wolff.
Breast Cancer Res Treat, 2011 Feb 26; 127(1). PMID: 21350820    Free PMC article.
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Christos Hatzis, Lajos Pusztai, +27 authors, W Fraser Symmans.
JAMA, 2011 May 12; 305(18). PMID: 21558518    Free PMC article.
Highly Cited.
Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer.
Leslie G Walker, Jennifer M Eremin, +14 authors, Oleg Eremin.
BMC Cancer, 2011 May 20; 11. PMID: 21592370    Free PMC article.
Breast cancer (non-metastatic).
Justin Stebbing, Geoff Delaney, Alastair Thompson.
BMJ Clin Evid, 2011 Jul 02; 2011. PMID: 21718560    Free PMC article.
Systematic Review.
Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.
Jordi Ginés, Eliazar Sabater, +3 authors, Miguel A Casado.
Clin Transl Oncol, 2011 Jul 22; 13(7). PMID: 21775276
Adjuvant Systemic Therapy of Breast Cancer.
Florian Schuetz.
Breast Care (Basel), 2011 Jul 23; 6(3). PMID: 21779222    Free PMC article.
Oligohydramnios associated with administration of weekly paclitaxel for triple-negative breast cancer during pregnancy.
M P Shieh, R S Mehta.
Ann Oncol, 2011 Jul 30; 22(9). PMID: 21799203    Free PMC article.
Management options in triple-negative breast cancer.
Christina A Minami, Debra U Chung, Helena R Chang.
Breast Cancer (Auckl), 2011 Aug 25; 5. PMID: 21863131    Free PMC article.
Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.
S Verma, L Provencher, R Dent.
Curr Oncol, 2011 Aug 30; 18(4). PMID: 21874117    Free PMC article.
Recent developments in treatment stratification for metastatic breast cancer.
Sarah Barton, Charles Swanton.
Drugs, 2011 Nov 01; 71(16). PMID: 22035512
How do I treat "triple-negative" disease.
Christos Vaklavas, Andres Forero-Torres.
Curr Treat Options Oncol, 2011 Nov 04; 12(4). PMID: 22048876
Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients.
Ying-Yi Qin, Hui Li, +8 authors, Jia He.
PLoS One, 2011 Nov 10; 6(11). PMID: 22069477    Free PMC article.
Systematic Review.
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Michael J Berger, Leslie J Dunlea, +3 authors, Charles L Shapiro.
Support Care Cancer, 2011 Nov 18; 20(9). PMID: 22089428    Free PMC article.
Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.
Yuko Tanabe, Kenji Hashimoto, +9 authors, Yasuhiro Fujiwara.
Int J Clin Oncol, 2011 Nov 23; 18(1). PMID: 22105895
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.
Christoph Thomssen, Anton Scharl, Nadia Harbeck.
Breast Care (Basel), 2011 Dec 14; 6(4). PMID: 22164127    Free PMC article.
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Joseph A Sparano, Molin Wang, +9 authors, Nancy E Davidson.
J Natl Cancer Inst, 2012 Jan 18; 104(5). PMID: 22250182    Free PMC article.
Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?
José Pérez-García, Javier Cortés.
Breast Cancer Res, 2012 Feb 03; 14(1). PMID: 22297134    Free PMC article.
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Daniel L Hertz, Alison A Motsinger-Reif, +4 authors, E Claire Dees.
Breast Cancer Res Treat, 2012 Apr 25; 134(1). PMID: 22527101    Free PMC article.
Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Kojiro Shimozuma, Yasuo Ohashi, +10 authors, Frederick H Hausheer.
Support Care Cancer, 2012 May 16; 20(12). PMID: 22584733
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
Yasuhiro Suzuki, Toshiaki Saeki, +10 authors, Yutaka Tokuda.
Int J Clin Oncol, 2012 May 16; 18(4). PMID: 22585426
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
Harold J Burstein, Martine J Piccart-Gebhart, +6 authors, Clifford A Hudis.
J Clin Oncol, 2012 May 23; 30(18). PMID: 22614986    Free PMC article.
Decline in the use of anthracyclines for breast cancer.
Sharon H Giordano, Yu-Li Lin, +2 authors, James S Goodwin.
J Clin Oncol, 2012 May 23; 30(18). PMID: 22614988    Free PMC article.
Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion.
Christian Jackisch, Hans-Joachim Lück, +5 authors, Marion Kiechle.
Breast Care (Basel), 2012 Jun 29; 7(2). PMID: 22740801    Free PMC article.
Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1.
Zhigang Bai, Zhongtao Zhang, +2 authors, Xuemei Ma.
Oncol Lett, 2012 Jun 29; 3(1). PMID: 22740869    Free PMC article.
Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Markus Joerger, Stefanie Kraff, +5 authors, Ulrich Jaehde.
Clin Pharmacokinet, 2012 Jul 19; 51(9). PMID: 22804749
The role of taxanes in the management of gastroesphageal cancer.
Paola Jimenez, Aditya Pathak, Alexandria T Phan.
J Gastrointest Oncol, 2012 Jul 20; 2(4). PMID: 22811858    Free PMC article.
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.
Bryan P Schneider, Fengmin Zhao, +10 authors, Joseph A Sparano.
J Clin Oncol, 2012 Aug 02; 30(25). PMID: 22851566    Free PMC article.
Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens.
Masaru Oba, Keisho Chin, +7 authors, Kiyohiko Hatake.
Oncol Lett, 2011 Mar 01; 2(2). PMID: 22866072    Free PMC article.
Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer.
Joseph A Sparano, Molin Wang, +10 authors, Nancy E Davidson.
Cancer, 2012 Aug 29; 118(23). PMID: 22926690    Free PMC article.
Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer.
Elizabeth Comen, Patrick G Morris, Larry Norton.
J Mammary Gland Biol Neoplasia, 2012 Sep 27; 17(3-4). PMID: 23011603
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.
Amye J Tevaarwerk, Robert J Gray, +7 authors, Joseph A Sparano.
Cancer, 2012 Oct 16; 119(6). PMID: 23065954    Free PMC article.
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.
Allison W Kurian, Daphne Y Lichtensztajn, +8 authors, Scarlett L Gomez.
Breast Cancer Res Treat, 2012 Nov 10; 137(1). PMID: 23139057    Free PMC article.
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.
Ahmed Aribi, Sigal Gery, +10 authors, H Phillip Koeffler.
Int J Cancer, 2012 Nov 21; 132(12). PMID: 23165325    Free PMC article.
Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer.
Hidemi Kawajiri, Tsutomu Takashima, +5 authors, Kosei Hirakawa.
Oncol Lett, 2012 Dec 04; 4(4). PMID: 23205071    Free PMC article.
Update on first-line treatment of advanced ovarian carcinoma.
Z Kemp, Ja Ledermann.
Int J Womens Health, 2013 Feb 05; 5. PMID: 23378788    Free PMC article.
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
Miguel Martín, Aleix Prat, +24 authors, Philip S Bernard.
Breast Cancer Res Treat, 2013 Feb 21; 138(2). PMID: 23423445    Free PMC article.
Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.
Eleni Andreopoulou, Joseph A Sparano.
Curr Breast Cancer Rep, 2013 Feb 27; 5(1). PMID: 23440080    Free PMC article.
Evaluation of the clinical benefits of nanoparticle albumin-bound paclitaxel in women with metastatic breast cancer in British Columbia.
A E Lohmann, C H Speers, S K Chia.
Curr Oncol, 2013 Apr 06; 20(2). PMID: 23559872    Free PMC article.
Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.
Ke-Da Yu, Guang-Yu Liu, +5 authors, Zhi-Ming Shao.
Oncologist, 2013 May 03; 18(5). PMID: 23635560    Free PMC article.
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
Hope S Rugo, Mario Campone, +9 authors, Xavier Pivot.
Breast Cancer Res Treat, 2013 May 08; 139(2). PMID: 23649189    Free PMC article.
Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.
Ming J Poi, Michael Berger, +6 authors, Robert Wesolowski.
Support Care Cancer, 2013 May 21; 21(10). PMID: 23686402    Free PMC article.
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Dawn L Hershman, Joseph M Unger, +12 authors, Kathy S Albain.
J Clin Oncol, 2013 Jun 05; 31(20). PMID: 23733756    Free PMC article.
Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy.
Sarah Crawford.
Front Pharmacol, 2013 Jun 28; 4. PMID: 23805101    Free PMC article.
Pancreatic cancer: why is it so hard to treat?
Paul E Oberstein, Kenneth P Olive.
Therap Adv Gastroenterol, 2013 Jul 03; 6(4). PMID: 23814611    Free PMC article.
Highly Cited.
Breast cancer survivorship issues.
Daniela Stan, Charles L Loprinzi, Kathryn J Ruddy.
Hematol Oncol Clin North Am, 2013 Aug 07; 27(4). PMID: 23915746    Free PMC article.
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Rebecca A Dent, Geoffrey J Lindeman, +7 authors, James Carmichael.
Breast Cancer Res, 2013 Sep 26; 15(5). PMID: 24063698    Free PMC article.
Highly Cited.
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
Eleni Andreopoulou, Ivette S Vigoda, +11 authors, Joseph A Sparano.
Breast Cancer Res Treat, 2013 Sep 27; 141(3). PMID: 24068539    Free PMC article.
Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.
Scheryll Alken, Catherine M Kelly.
Cancer Manag Res, 2013 Oct 22; 5. PMID: 24143122    Free PMC article.
Assessment of paclitaxel induced sensory polyneuropathy with "Catwalk" automated gait analysis in mice.
Petra Huehnchen, Wolfgang Boehmerle, Matthias Endres.
PLoS One, 2013 Oct 22; 8(10). PMID: 24143194    Free PMC article.
Dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node-positive breast cancer.
Hamid Reza Mirzaei, Parisa Sabet Rasekh, +5 authors, Parastoo Hajian.
Int J Breast Cancer, 2013 Nov 05; 2013. PMID: 24187626    Free PMC article.
A case of primary metastatic glassy cell carcinoma of the uterine cervix that responded to combined docetaxel and carboplatin.
Yuji Ukita, Hiroshi Tsubamoto, +2 authors, Hiroaki Shibahara.
Gynecol Oncol Case Rep, 2013 Dec 29; 6. PMID: 24371710    Free PMC article.
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.
Isabella Sperduti, Patrizia Vici, +6 authors, Clara Natoli.
J Exp Clin Cancer Res, 2014 Jan 21; 32. PMID: 24438135    Free PMC article.
Systematic Review.
BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
Melissa Burgess, Shannon Puhalla.
Front Oncol, 2014 Mar 01; 4. PMID: 24579064    Free PMC article.
Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer.
Katsunori Tozuka, Jun Horiguchi, +7 authors, Izumi Takeyoshi.
Mol Clin Oncol, 2013 Jan 01; 1(1). PMID: 24649129    Free PMC article.
Clinical utility of aromatase inhibitors as adjuvant treatment in postmenopausal early breast cancer.
Arturo Loaiza-Bonilla, Francisco Socola, Stefan Glück.
Clin Med Insights Womens Health, 2013 Jan 01; 6. PMID: 24665209    Free PMC article.
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.
Vinay Prasad, Paul R Massey, Tito Fojo.
J Clin Oncol, 2014 Apr 09; 32(15). PMID: 24711558    Free PMC article.
Expression of murine 5-aminolevulinate synthase variants causes protoporphyrin IX accumulation and light-induced mammalian cell death.
Erica J Fratz, Gregory A Hunter, Gloria C Ferreira.
PLoS One, 2014 Apr 11; 9(4). PMID: 24718052    Free PMC article.
Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.
Matthieu Picard, Mariana C Castells.
Clin Rev Allergy Immunol, 2014 Apr 18; 49(2). PMID: 24740483
Combination therapy of albumin-bound Paclitaxel and Carboplatin as first line therapy in a patient with ovarian cancer.
K N Srinivasan, Amit Rauthan, R Gopal.
Case Rep Oncol Med, 2014 May 08; 2014. PMID: 24804130    Free PMC article.
Systemic treatment strategies for triple-negative breast cancer.
Budhi Singh Yadav, Suresh C Sharma, Priyanka Chanana, Swaty Jhamb.
World J Clin Oncol, 2014 May 16; 5(2). PMID: 24829859    Free PMC article.
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
D Lu, A Joshi, +5 authors, J Y Jin.
CPT Pharmacometrics Syst Pharmacol, 2014 May 23; 3. PMID: 24850445    Free PMC article.
Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Rachel Webber-Foster, Giorgi Kvizhinadze, Gareth Rivalland, Tony Blakely.
Pharmacoeconomics, 2014 May 27; 32(7). PMID: 24859241
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.
Carlos H Barcenas, Jiangong Niu, +6 authors, Sharon H Giordano.
J Clin Oncol, 2014 May 29; 32(19). PMID: 24868022    Free PMC article.
Epiphora in lung cancer patients receiving docetaxel: a case series.
Tomoko Yamagishi, Nobuaki Ochi, +2 authors, Nagio Takigawa.
BMC Res Notes, 2014 Jun 03; 7. PMID: 24886618    Free PMC article.
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
Maria Y Ho, John R Mackey.
Cancer Manag Res, 2014 Jun 07; 6. PMID: 24904223    Free PMC article.
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.
George Fountzilas, Urania Dafni, +20 authors, Meletios-Athanassios Dimopoulos.
BMC Cancer, 2014 Jul 17; 14. PMID: 25026897    Free PMC article.
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer.
Hyun Jung Lee, Dae-Seog Heo, +9 authors, Yung-Jue Bang.
Cancer Res Treat, 2014 Jul 21; 46(3). PMID: 25038758    Free PMC article.
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Sylvia Adams, Robert J Gray, +13 authors, Sunil S Badve.
J Clin Oncol, 2014 Jul 30; 32(27). PMID: 25071121    Free PMC article.
Highly Cited.
Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines.
Jennifer A Crozier, Abhisek Swaika, Alvaro Moreno-Aspitia.
World J Clin Oncol, 2014 Aug 13; 5(3). PMID: 25114866    Free PMC article.
Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
Nigel Fleeman, Adrian Bagust, +4 authors, Yenal Dundar.
Pharmacoeconomics, 2014 Aug 21; 33(1). PMID: 25138171
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.
Cornelia Liedtke, Marc Thill, +2 authors, AGO Breast Committee.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177261    Free PMC article.
Dose-dense epirubicin and cyclophosphamide followed by weekly Paclitaxel in node-positive breast cancer.
Hamid Reza Mirzaei, Fatemeh Nasrollahi, +3 authors, Parastoo Hajian.
Chemother Res Pract, 2014 Oct 03; 2014. PMID: 25276426    Free PMC article.
Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.
Katrina N Slaughter, Kathleen N Moore, Robert S Mannel.
Curr Oncol Rep, 2014 Oct 09; 16(11). PMID: 25292279
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Pregnancy-associated breast cancer: optimal treatment options.
Elyce Cardonick.
Int J Womens Health, 2014 Nov 15; 6. PMID: 25395871    Free PMC article.
Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
Patricia R Blank, Martin Filipits, +11 authors, Michael Gnant.
Pharmacoeconomics, 2014 Nov 19; 33(2). PMID: 25404424    Free PMC article.
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
George T Budd, William E Barlow, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2014 Nov 26; 33(1). PMID: 25422488    Free PMC article.
Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy.
Ka-Eun Yoo, Rae Young Kang, +6 authors, Byung Koo Lee.
Support Care Cancer, 2014 Dec 17; 23(7). PMID: 25500718
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Michael J Berger, Craig Vargo, +9 authors, Maryam B Lustberg.
Support Care Cancer, 2014 Dec 19; 23(7). PMID: 25519756    Free PMC article.
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Chau Dang, Neil Iyengar, +17 authors, Clifford Hudis.
J Clin Oncol, 2014 Dec 31; 33(5). PMID: 25547504    Free PMC article.
Ovarian cancer standard of care: are there real alternatives?
Chiara Della Pepa, Giuseppe Tonini, +5 authors, Sando Pignata.
Chin J Cancer, 2015 Jan 06; 34(1). PMID: 25556615    Free PMC article.
Report from the 37th san antonio breast cancer symposium, 9-13th december 2014, Texas, USA.
M Ahmed, E Esposito.
Ecancermedicalscience, 2015 Mar 03; 9. PMID: 25729421    Free PMC article.
Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.
A Eisen, G G Fletcher, +5 authors, members of the Early Breast Cancer Systemic Therapy Consensus Panel.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848340    Free PMC article.
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
S Gandhi, G G Fletcher, +4 authors, M E Trudeau.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848343    Free PMC article.
Therapies for triple negative breast cancer.
Eleni Andreopoulou, Sarah J Schweber, Joseph A Sparano, Hayley M McDaid.
Expert Opin Pharmacother, 2015 Apr 18; 16(7). PMID: 25881743    Free PMC article.
Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.
Meyha N Swaroop, Chantal M Ferguson, +8 authors, Alphonse G Taghian.
Breast Cancer Res Treat, 2015 May 06; 151(2). PMID: 25940996    Free PMC article.
nab-Paclitaxel dose and schedule in breast cancer.
Miguel Martín.
Breast Cancer Res, 2015 Jun 13; 17. PMID: 26067995    Free PMC article.
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Joseph A Sparano, Fengmin Zhao, +7 authors, Nancy E Davidson.
J Clin Oncol, 2015 Jun 17; 33(21). PMID: 26077235    Free PMC article.
Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma.
Hugo Ford, Ioannis Gounaris.
Therap Adv Gastroenterol, 2015 Jul 03; 8(4). PMID: 26136837    Free PMC article.
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.
Bryan P Schneider, Lang Li, +20 authors, George W Sledge.
Clin Cancer Res, 2015 Jul 04; 21(22). PMID: 26138065    Free PMC article.
Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.
Shivani S Shinde, Drew Seisler, +5 authors, Charles L Loprinzi.
Support Care Cancer, 2015 Jul 15; 24(2). PMID: 26155765
Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas.
Amir Sonnenblick, Feras Eleyan, +5 authors, Daniela Katz.
Mol Clin Oncol, 2015 Jul 15; 3(4). PMID: 26171190    Free PMC article.
Current approaches in treatment of triple-negative breast cancer.
Hanan Ahmed Wahba, Hend Ahmed El-Hadaad.
Cancer Biol Med, 2015 Jul 16; 12(2). PMID: 26175926    Free PMC article.
Highly Cited. Review.
Progress in adjuvant chemotherapy for breast cancer: an overview.
Jesus Anampa, Della Makower, Joseph A Sparano.
BMC Med, 2015 Aug 19; 13. PMID: 26278220    Free PMC article.
Highly Cited. Review.
Long term side effects of adjuvant chemotherapy in patients with early breast cancer.
Jessica J Tao, Kala Visvanathan, Antonio C Wolff.
Breast, 2015 Aug 25; 24 Suppl 2. PMID: 26299406    Free PMC article.
Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series.
Takayoshi Kiba, Nao Morii, +4 authors, Hiroyasu Yamashiro.
Breast Cancer (Dove Med Press), 2015 Sep 12; 7. PMID: 26357489    Free PMC article.
Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment.
João Conde, Nuria Oliva, +2 authors, Natalie Artzi.
Nat Mater, 2015 Dec 08; 15(3). PMID: 26641016    Free PMC article.
Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review.
Cloé Brami, Ting Bao, Gary Deng.
Crit Rev Oncol Hematol, 2015 Dec 15; 98. PMID: 26652982    Free PMC article.
Systematic Review.
Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer.
Mohamed Alsharedi, Todd Gress, +2 authors, Maria Tria Tirona.
Med Oncol, 2016 Feb 18; 33(3). PMID: 26883934
A Case of Advanced Extramammary Paget's Disease Successfully Controlled by Monthly but Not Weekly Docetaxel Chemotherapy.
Yuki Yoshihara, Munenari Itoh, Yoshimasa Nobeyama, Hidemi Nakagawa.
Case Rep Oncol, 2016 Mar 05; 9(1). PMID: 26933412    Free PMC article.
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
John K Chan, Mark F Brady, +12 authors, Bradley J Monk.
N Engl J Med, 2016 Mar 05; 374(8). PMID: 26933849    Free PMC article.
Highly Cited.
Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.
Heather Greenlee, Katherine D Crew, +9 authors, Dawn L Hershman.
Breast Cancer Res Treat, 2016 Mar 26; 156(3). PMID: 27013473    Free PMC article.
Monitoring Apoptosis of Breast Cancer Xenograft After Paclitaxel Treatment With 99mTc-Labeled Duramycin SPECT/CT.
Rui Luo, Lei Niu, +7 authors, Feng Wang.
Mol Imaging, 2016 Apr 01; 15. PMID: 27030401    Free PMC article.
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer.
Simon B Zeichner, Hiromi Terawaki, Keerthi Gogineni.
Breast Cancer (Auckl), 2016 Apr 05; 10. PMID: 27042088    Free PMC article.
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients.
Volker Möbus.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051389    Free PMC article.
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.
Chang Gon Kim, Joohyuk Sohn, +8 authors, Gun Min Kim.
J Breast Cancer, 2016 Apr 12; 19(1). PMID: 27064666    Free PMC article.
Metronomic Chemotherapy for Metastatic Breast Cancer - a Systematic Review of the Literature.
M Banys-Paluchowski, F Schütz, +2 authors, T Fehm.
Geburtshilfe Frauenheilkd, 2016 May 31; 76(5). PMID: 27239061    Free PMC article.
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
L M Smyth, N M Iyengar, +15 authors, C T Dang.
Breast Cancer Res Treat, 2016 Jun 17; 158(1). PMID: 27306421    Free PMC article.
Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.
Liyu Jiang, Chuyu Jing, +6 authors, Qifeng Yang.
Oncol Lett, 2016 Jul 23; 12(2). PMID: 27446451    Free PMC article.
Adjuvant systemic therapy in older women with breast cancer.
Julieta Leone, Bernardo Amadeo Leone, José Pablo Leone.
Breast Cancer (Dove Med Press), 2016 Aug 16; 8. PMID: 27524919    Free PMC article.
Dermatological adverse events with taxane chemotherapy.
Vincent Sibaud, Nicole R Lebœuf, +8 authors, Mario E Lacouture.
Eur J Dermatol, 2016 Oct 30; 26(5). PMID: 27550571    Free PMC article.
Systematic Review.
Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.
Rae Young Kang, Kyung Sook Yoo, +4 authors, Yu Jeung Lee.
Support Care Cancer, 2016 Oct 01; 25(2). PMID: 27687722
Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy.
Gabriel Ramirez, Ashley R Proctor, +11 authors, Regine Choe.
Biomed Opt Express, 2016 Oct 05; 7(9). PMID: 27699124    Free PMC article.
Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.
Raghav Sundar, Anand D Jeyasekharan, +16 authors, Soo-Chin Lee.
PLoS One, 2016 Oct 08; 11(10). PMID: 27716814    Free PMC article.
Triple-negative breast cancer: is there a treatment on the horizon?
Hui Yao, Guangchun He, +4 authors, Xiyun Deng.
Oncotarget, 2016 Oct 22; 8(1). PMID: 27765921    Free PMC article.
Highly Cited. Review.
BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.
Heather Greenlee, Dawn L Hershman, +4 authors, Lawrence H Kushi.
J Natl Cancer Inst, 2016 Oct 30; 109(2). PMID: 27794123    Free PMC article.
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.
Bryan P Schneider, Fei Shen, +14 authors, George W Sledge.
Clin Cancer Res, 2016 Dec 21; 23(1). PMID: 27993963    Free PMC article.
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Jessica Ley, Tanya M Wildes, +2 authors, Douglas Adkins.
Med Oncol, 2017 Jan 13; 34(2). PMID: 28078561    Free PMC article.
Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Kenji Tamura, Kenichi Inoue, +19 authors, Yasuhiro Fujiwara.
Cancer Sci, 2017 Mar 04; 108(5). PMID: 28256066    Free PMC article.
Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
Qiu-Wen Tan, Ting Luo, +5 authors, Qing Lv.
Chin J Cancer, 2017 Mar 09; 36(1). PMID: 28270181    Free PMC article.
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Joanne L Blum, Patrick J Flynn, +19 authors, Norman Wolmark.
J Clin Oncol, 2017 Apr 12; 35(23). PMID: 28398846    Free PMC article.
Highly Cited.
Critically short telomeres and toxicity of chemotherapy in early breast cancer.
Miguel Quintela-Fandino, Nora Soberon, +23 authors, Maria A Blasco.
Oncotarget, 2017 Apr 21; 8(13). PMID: 28423524    Free PMC article.
Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy.
Yuko Tanabe, Hitoshi Tsuda, +7 authors, Kenji Tamura.
Cancer Sci, 2017 May 06; 108(7). PMID: 28474753    Free PMC article.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
David Cameron, James P Morden, +22 authors, TACT2 Investigators.
Lancet Oncol, 2017 Jun 11; 18(7). PMID: 28600210    Free PMC article.
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Tessa G Steenbruggen, Mette S van Ramshorst, +3 authors, Gabe S Sonke.
Drugs, 2017 Jun 16; 77(12). PMID: 28616845
Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study.
Maki Tanioka, Satoshi Yamaguchi, +7 authors, Junzo Kigawa.
Med Oncol, 2017 Jul 07; 34(8). PMID: 28681218
Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel.
Hua He, Yanguang Cao.
J Pharmacokinet Pharmacodyn, 2017 Sep 02; 44(5). PMID: 28861682    Free PMC article.
Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?
Boris Freidlin, Edward L Korn.
J Natl Cancer Inst, 2017 Sep 28; 109(9). PMID: 28954288    Free PMC article.
Taxane-Induced Peripheral Neurotoxicity.
Roser Velasco, Jordi Bruna.
Toxics, 2015 Apr 28; 3(2). PMID: 29056655    Free PMC article.
Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.
Marcus Vetter, Spyridon Fokas, +6 authors, Rosanna Zanetti-Dällenbach.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088896    Free PMC article.
Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer.
Jiantang Zhang, Fangmeng Fu, +6 authors, Chuan Wang.
Oncotarget, 2017 Nov 09; 8(46). PMID: 29113420    Free PMC article.
Targeting bromodomain and extraterminal proteins in breast cancer.
Jennifer M Sahni, Ruth A Keri.
Pharmacol Res, 2017 Nov 21; 129. PMID: 29154989    Free PMC article.
Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.
Steffen Dörfel, Claus-Christoph Steffens, +6 authors, TMK-Group (Tumour Registry Breast Cancer).
Breast Cancer, 2017 Dec 06; 25(3). PMID: 29204847    Free PMC article.
Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario.
Kristi Orbaugh, Joanne C Ryan, Lynn Pfeuffer.
J Adv Pract Oncol, 2016 Jul 01; 7(5). PMID: 29282430    Free PMC article.
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Luca Gianni, Mauro Mansutti, +18 authors, Ignacio Tusquets.
JAMA Oncol, 2018 Jan 13; 4(3). PMID: 29327055    Free PMC article.
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).
Dawn L Hershman, Joseph M Unger, +11 authors, Kathy S Albain.
J Natl Cancer Inst, 2018 Jan 24; 110(6). PMID: 29361042    Free PMC article.
Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity.
Luke P Legakis, John W Bigbee, S Stevens Negus.
Behav Pharmacol, 2018 Jan 26; 29(2 and 3-Spec Issue). PMID: 29369054    Free PMC article.
Breast Cancer in Nepal: Current status and future directions.
Mohan Giri, Mamata Giri, +2 authors, Bijay Pariyar.
Biomed Rep, 2018 Mar 16; 8(4). PMID: 29541453    Free PMC article.
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
Frankie Ann Holmes, Beth A Hellerstedt, +11 authors, Joyce O'Shaughnessy.
Cancer Med, 2018 Mar 28; 7(6). PMID: 29582557    Free PMC article.
Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Anna Weiss, Sami I Bashour, +2 authors, Nuhad K Ibrahim.
Breast Cancer Res, 2018 Apr 18; 20(1). PMID: 29661243    Free PMC article.
Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis.
William H Isacoff, Howard A Reber, +5 authors, O Joe Hines.
Target Oncol, 2018 Jun 09; 13(4). PMID: 29882102    Free PMC article.
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Karen A Cadoo, Peter A Kaufman, +3 authors, Tiffany A Traina.
Clin Breast Cancer, 2018 Jun 14; 18(6). PMID: 29895438    Free PMC article.
Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial.
Akiko Hanai, Hiroshi Ishiguro, +8 authors, Tadao Tsuboyama.
J Natl Cancer Inst, 2018 Jun 21; 110(2). PMID: 29924336    Free PMC article.
Metastatic gynecologic malignancies: advances in treatment and management.
John K Chan, Stephanie Chow, +3 authors, Robert L Coleman.
Clin Exp Metastasis, 2018 Jun 23; 35(5-6). PMID: 29931499
A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Ting Bao, Andrew D Seidman, +10 authors, Jun J Mao.
Eur J Cancer, 2018 Jul 17; 101. PMID: 30007894    Free PMC article.
Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies.
Binghe Xu, Zhimin Shao, +7 authors, Shu Wang.
Chin J Cancer Res, 2018 Jul 27; 30(3). PMID: 30046227    Free PMC article.
Overview of Breast Cancer Therapy.
Tracy-Ann Moo, Rachel Sanford, Chau Dang, Monica Morrow.
PET Clin, 2018 Aug 14; 13(3). PMID: 30100074    Free PMC article.
Cardio-oncology: protecting the heart from curative breast cancer treatment.
Jenica N Upshaw.
Gland Surg, 2018 Sep 04; 7(4). PMID: 30175052    Free PMC article.
Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers.
Andrew Poklepovic, Yuesheng Qu, +6 authors, Rakesh C Kukreja.
Cardiooncology, 2018 Sep 18; 4. PMID: 30221011    Free PMC article.
QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer.
Hiromi Okuyama, Seigo Nakamura, +4 authors, Yasuhisa Kato.
Eur J Breast Health, 2018 Oct 06; 14(4). PMID: 30288492    Free PMC article.
Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis.
Wu Ding, Zhian Li, +3 authors, Chuanjian Tu.
Medicine (Baltimore), 2018 Oct 20; 97(42). PMID: 30335021    Free PMC article.
Systematic Review.
Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.
Florence R Wilson, Megan E Coombes, +7 authors, Chris Cameron.
Syst Rev, 2018 Nov 16; 7(1). PMID: 30428932    Free PMC article.
Systematic Review.
Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.
Amanda Fitzpatrick, Andrew Tutt.
Ther Adv Med Oncol, 2019 Nov 09; 11. PMID: 31700549    Free PMC article.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Andrew R Clamp, Elizabeth C James, +26 authors, Jonathan A Ledermann.
Lancet, 2019 Dec 04; 394(10214). PMID: 31791688    Free PMC article.
Identification of genes associated with SiHa cell sensitivity to paclitaxel by CRISPR-Cas9 knockout screening.
Wei Wei, Yue He, Yu-Mei Wu.
Int J Clin Exp Pathol, 2018 Apr 01; 11(4). PMID: 31938303    Free PMC article.
Cancer Cell Membrane-Coated Nanoparticles for Cancer Management.
Jenna C Harris, Mackenzie A Scully, Emily S Day.
Cancers (Basel), 2019 Nov 27; 11(12). PMID: 31766360    Free PMC article.
Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer.
Tala M Abu Samaan, Marek Samec, +2 authors, Dietrich Büsselberg.
Biomolecules, 2019 Dec 01; 9(12). PMID: 31783552    Free PMC article.
Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer.
Takaaki Oba, Kazuma Maeno, +4 authors, Ken-Ichi Ito.
BMC Cancer, 2020 Feb 29; 20(1). PMID: 32106833    Free PMC article.
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.
Daniel L Hertz, Kelley M Kidwell, +9 authors, N Lynn Henry.
Clin Cancer Res, 2018 Apr 29; 24(15). PMID: 29703818    Free PMC article.
Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
John Esther, Benjamin L Maughan, +2 authors, Andrew W Hahn.
Curr Treat Options Oncol, 2019 Feb 12; 20(2). PMID: 30741354
Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.
Hideyuki Shimizu, Shoichiro Takeishi, Hirokazu Nakatsumi, Keiichi I Nakayama.
JCI Insight, 2019 Mar 05; 4(4). PMID: 30830867    Free PMC article.
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).
Ji-Yeon Kim, Seri Park, +18 authors, Korean Cancer Study Group.
Cancer Commun (Lond), 2019 May 30; 39(1). PMID: 31138332    Free PMC article.
Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
Lara Sánchez-Barroso, Maria Apellaniz-Ruiz, +17 authors, Cristina Rodríguez-Antona.
Oncologist, 2018 Nov 25; 24(8). PMID: 30470691    Free PMC article.
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Rui Wang, Lillian M Smyth, +7 authors, Chau T Dang.
Oncologist, 2019 Jan 04; 24(8). PMID: 30602614    Free PMC article.
Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer.
Xenia Elena Bacinschi, Rodica Maricela Anghel, +3 authors, Silvia Mihaela Ilie.
Cancer Manag Res, 2020 Mar 13; 12. PMID: 32161494    Free PMC article.
Poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles containing oligo(lactic acid)8-paclitaxel prodrug: In Vivo conversion and antitumor efficacy.
Yu Tong Tam, Dae Hwan Shin, Karen E Chen, Glen S Kwon.
J Control Release, 2019 Feb 23; 298. PMID: 30790593    Free PMC article.
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Yuko Tanabe, Seiji Shiraishi, +13 authors, Chikako Shimizu.
BMC Cancer, 2020 Apr 17; 20(1). PMID: 32295642    Free PMC article.
Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.
Chen-Yu Huang, Min Cheng, +4 authors, Peng-Hui Wang.
Int J Environ Res Public Health, 2020 Apr 01; 17(7). PMID: 32224896    Free PMC article.
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Priyanka Sharma, William E Barlow, +19 authors, Daniel F Hayes.
J Clin Oncol, 2019 Oct 29; 37(36). PMID: 31657982    Free PMC article.
Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression.
Qingxiang Lin, Yuan He, +10 authors, Yihua Chen.
Adv Sci (Weinh), 2020 May 10; 7(9). PMID: 32382484    Free PMC article.
Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer.
Ashok K Vaid, Aseem Khurana, +6 authors, Kush Gupta.
World J Oncol, 2020 Jun 05; 11(3). PMID: 32494317    Free PMC article.
Use of oral paclitaxel for the treatment of bladder tumors in dogs.
Hyung-Kyu Chae, Ji-In Yang, +4 authors, Hwa-Young Youn.
J Vet Med Sci, 2020 Apr 07; 82(5). PMID: 32249251    Free PMC article.
Genome-wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer.
Boram Park, Sung Hoon Sim, +2 authors, In Hae Park.
Cancer Sci, 2020 May 08; 111(7). PMID: 32378780    Free PMC article.
Risk Factors for Lymphedema in Breast Cancer Survivors Following Axillary Lymph Node Dissection.
Yoshiteru Akezaki, Ritsuko Tominaga, +7 authors, Shinsuke Sugihara.
Prog Rehabil Med, 2020 Aug 14; 4. PMID: 32789268    Free PMC article.
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Ke-Da Yu, Fu-Gui Ye, +19 authors, Zhi-Ming Shao.
JAMA Oncol, 2020 Aug 14; 6(9). PMID: 32789480    Free PMC article.
Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer.
Zhen Zhao, Yuanke Li, +3 authors, Kun Cheng.
Sci Adv, 2020 Aug 25; 6(29). PMID: 32832636    Free PMC article.
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
Yongzhen Chen, Fang Fang, +9 authors, Daniel L Hertz.
Pharmacogenomics, 2020 Jul 24; 21(12). PMID: 32700628    Free PMC article.
Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients.
Hideo Shigematsu, Taizo Hirata, +2 authors, Shinji Ozaki.
Support Care Cancer, 2020 Feb 10; 28(10). PMID: 32036471    Free PMC article.
Innovative Approach for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Pilot Study With the Hilotherm Device, the Poliambulanza Hospital Experience.
Ester Oneda, Fausto Meriggi, +5 authors, Alberto Zaniboni.
Integr Cancer Ther, 2020 Aug 29; 19. PMID: 32856475    Free PMC article.
Neuronal Protection for Chemotherapy Neuropathy Prevention?
Charles L Loprinzi, Dawn L Hershman, Nathan Staff.
J Natl Cancer Inst, 2019 May 17; 112(1). PMID: 31093679    Free PMC article.
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.
Shani Paluch-Shimon, Nathan I Cherny, +4 authors, Fatima Cardoso.
ESMO Open, 2020 Sep 08; 5(5). PMID: 32893189    Free PMC article.
Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer.
Qing Li, Jiani Wang, +9 authors, Binghe Xu.
Chin J Cancer Res, 2020 Sep 24; 32(4). PMID: 32963461    Free PMC article.
Trastuzumab-Based Combination Chemotherapy in Patients with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Carcinoma ex Pleomorphic Adenoma.
Yohei Arihara, Kazuyuki Murase, +8 authors, Junji Kato.
Case Rep Oncol, 2019 Jan 29; 11(3). PMID: 30687059    Free PMC article.
Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates.
Fernando Kude de Almeida, Daniela Dornelles Rosa.
Breast Care (Basel), 2019 Feb 26; 13(6). PMID: 30800040    Free PMC article.
Short-term fasting accompanying chemotherapy as a supportive therapy in gynecological cancer: protocol for a multicenter randomized controlled clinical trial.
Daniela Koppold-Liebscher, Christian S Kessler, +11 authors, Andreas Michalsen.
Trials, 2020 Oct 17; 21(1). PMID: 33059765    Free PMC article.
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.
Jennifer Y Sheng, Cesar A Santa-Maria, +18 authors, Karen L Smith.
JCO Oncol Pract, 2020 Jul 01; 16(10). PMID: 32603252    Free PMC article.
Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment.
Arthur Foulon, Pierrick Theret, Lise Rodat-Despoix, Philippe Kischel.
Cancers (Basel), 2020 Sep 20; 12(9). PMID: 32947780    Free PMC article.
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
Amelie de Gregorio, Lothar Häberle, +22 authors, Wolfgang Janni.
Breast Cancer Res, 2020 Oct 25; 22(1). PMID: 33097092    Free PMC article.
Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial.
Takanori Kin, Shoichiro Ohtani, +9 authors, Koichi Hiraki.
World J Oncol, 2020 Oct 30; 11(5). PMID: 33117463    Free PMC article.
Comparison of chemotherapy effects on mechanical sensitivity and food-maintained operant responding in male and female rats.
Luke P Legakis, Clare M Diester, +2 authors, Sidney Stevens Negus.
Behav Pharmacol, 2019 Dec 14; 31(5). PMID: 31833969    Free PMC article.
Efficacy and Safety of Acupuncture against Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis.
Yuxia Jin, Yunxia Wang, +2 authors, Qi Zhang.
Evid Based Complement Alternat Med, 2020 Nov 24; 2020. PMID: 33224260    Free PMC article.
Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Toru Watanabe, Masaru Kuranami, +7 authors, Yasuo Ohashi.
Cancer, 2017 Jan 13; 123(5). PMID: 28081304    Free PMC article.
Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer.
Eunpi Cho, Qian Wu, +5 authors, Georgiana Ellis.
Breast J, 2018 Mar 14; 24(4). PMID: 29532546    Free PMC article.
Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial.
O Abdel-Rahman.
Clin Transl Oncol, 2018 Jun 30; 21(2). PMID: 29956074
The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
Ana Luísa de Castro Baccarin, Macilon Nonato Irene, +5 authors, Auro Del Giglio.
Support Care Cancer, 2018 Aug 03; 27(3). PMID: 30069696
Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Uanderson Resende, César Cabello, Susana Oliveira Botelho Ramalho, Luiz Carlos Zeferino.
BMC Cancer, 2019 Jun 19; 19(1). PMID: 31208353    Free PMC article.
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
Andreas Schneeweiss, Carsten Denkert, +5 authors, Hans-Joachim Lück.
Geburtshilfe Frauenheilkd, 2019 Jun 21; 79(6). PMID: 31217629    Free PMC article.
Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer.
Shoji Nagao, Kasumi Yamamoto, +4 authors, Junzo Kigawa.
Int J Clin Oncol, 2020 Sep 23; 26(1). PMID: 32960420
Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Junji Tsurutani, Fumikata Hara, +13 authors, Hirofumi Mukai.
Breast, 2020 Dec 21; 55. PMID: 33341707    Free PMC article.
Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer.
Samilia Obeng-Gyasi, Anne O'Neill, +7 authors, Ruth C Carlos.
Cancer Med, 2020 Dec 03; 10(1). PMID: 33264502    Free PMC article.
Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients.
M E Tesch, S K Chia, C E Simmons, N LeVasseur.
Breast Cancer Res Treat, 2021 Feb 22; 187(1). PMID: 33611678
Efficacy and safety of cyclophosphamide in anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Yi-Kun Kang, Yi-Ran Si, Guang-Yu An, Peng Yuan.
Gland Surg, 2021 Feb 27; 10(1). PMID: 33633981    Free PMC article.
Injectable Glycol Chitosan Hydrogel Containing Folic Acid-Functionalized Cyclodextrin-Paclitaxel Complex for Breast Cancer Therapy.
Hoon Hyun, Min Ho Park, +5 authors, Dae Hyeok Yang.
Nanomaterials (Basel), 2021 Jan 31; 11(2). PMID: 33513732    Free PMC article.
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.
Gwen M H E Dackus, Katarzyna Jóźwiak, +5 authors, Sabine C Linn.
Breast Cancer Res Treat, 2020 Oct 29; 185(3). PMID: 33113088    Free PMC article.
Influence of serum inflammatory cytokines on cytochrome P450 drug metabolising activity during breast cancer chemotherapy: a patient feasibility study.
Rebekah L I Crake, Matthew R Strother, +5 authors, Margaret J Currie.
Sci Rep, 2021 Mar 13; 11(1). PMID: 33707475    Free PMC article.